Search results for "Neoplastic"

showing 10 items of 2901 documents

Colorectal cancer: pharmacogenetics support for the correct drug prescription

2019

Pharmacogenetics (PGx) in clinical practice is a tool that the clinician can use to guide, in a personalized way, the most suitable treatment that will be administered to the patient. The objective of this review is to summarize in a practical and accessible rational way, the advances that currently exist for the application of PGx in colorectal cancer chemotherapy management through the study of the patients’ germline polymorphisms. To define the polymorphisms that can be applied, we rely on three fundamental cornerstones: the recommendations of drug regulatory agencies; the implementation guidelines prepared by expert consortia in PGx and information from clinical annotations (the drug/p…

Drugmedicine.medical_specialtyPharmGKBColorectal cancermedia_common.quotation_subjectAntineoplastic AgentsDrug PrescriptionsPolymorphism Single NucleotideGeneticsmedicineAnimalsHumansPrecision MedicineMedical prescriptionIntensive care medicinemedia_commonPharmacologybusiness.industryfood and beveragesEvidence-based medicinemedicine.diseaseClinical PracticePharmacogeneticsMolecular MedicineColorectal NeoplasmsbusinessPharmacogeneticsPharmacogenomics
researchProduct

Assessing the risk to health care staff from long-term exposure to anticancer drugs--the case of monoclonal antibodies.

2010

Today the occupational health and safety risk involved when handling most anticancer drugs is well recognized and, as a result of regulatory requirements, safety measures have been established. There is little knowledge about the occupational hazard posed by handling monoclonal antibodies assigned to ATC Class L01XC. The aim of our study was to evaluate the occupational risk of monoclonal antibodies. Using the information obtained in a systematic review of the literature, the potentially dangerous properties of the active drug substances were assessed using a specially devised algorithm. As a result, all monoclonal antibodies in question were categorized as substances with developmental to…

Drugmedicine.medical_specialtymedicine.drug_classGemtuzumab ozogamicinmedia_common.quotation_subjectMEDLINEAntineoplastic AgentsMonoclonal antibodyRisk AssessmentOccupational safety and healthOccupational ExposureHealth caremedicineAnimalsHumansPharmacology (medical)Intensive care medicineOccupational Healthmedia_commonbusiness.industryAntibodies MonoclonalMolecular WeightOncologyHealth OccupationsImmunologyOccupational exposureRisk assessmentbusinessAlgorithmsmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Management of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines

2012

Extravasation is the process by which any liquid (fluid or drug) accidentally leaks into the surrounding tissue. In terms of cancer therapy, extravasation refers to the inadvertent infiltration of chemotherapy into the subcutaneous or subdermal tissues surrounding the intravenous or intra-arterial administration site. Extravasated drugs are classified according to their potential for causing damage as ‘vesicant’, ‘irritant’ and ‘nonvesicant’ (Table 1). Some vesicant drugs are further classified into two groups: DNA binding and non-DNA binding. Allwood et al. (2002) divided the drugs into vesicants, exfoliants, irritants, inflammitants and neutrals.

Drugmedicine.medical_specialtymedicine.medical_treatmentmedia_common.quotation_subjectAntidotesMEDLINECancer therapyAntineoplastic AgentsDiagnosis DifferentialRisk FactorsNeoplasmsHumansMedicineIntensive care medicinemedia_commonChemotherapyOncology (nursing)business.industryGeneral MedicineHematologymedicine.diseaseChemotherapy regimenExtravasationSurgeryClinical PracticeOncologybusinessInfiltration (medical)Extravasation of Diagnostic and Therapeutic MaterialsAnnals of Oncology
researchProduct

Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review

2021

Although cancer and diabetes are common diseases, the relationship between diabetes, neuropathy and the risk of developing peripheral sensory neuropathy while or after receiving chemotherapy is uncertain. In this review, we highlight the effects of chemotherapy on the onset or progression of neuropathy in diabetic patients. We searched the literature in Medline and Scopus, covering all entries until 31 January 2021. The inclusion and exclusion criteria were: (1) original article (2) full text published in English or Spanish; (3) neuropathy was specifically assessed (4) the authors separately analyzed the outcomes in diabetic patients. A total of 259 papers were retrieved. Finally, eight art…

Drugmedicine.medical_specialtymedicine.medical_treatmentmedia_common.quotation_subjectautonomic dysfunctionMEDLINEAntineoplastic AgentsReviewDiabetes mellitusInternal medicineNeoplasmscold sensitivitymedicineDiabetes MellitusHumansRC254-282media_commonChemotherapybusiness.industrycytostatic drugsCancerPeripheral Nervous System DiseasestoxicityNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseRadiation therapyside effectsregimensPeripheral neuropathyInclusion and exclusion criteriabusinessCurrent Oncology
researchProduct

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

2007

The ubiquitin-proteasome pathway is the main proteolytic system present in the nucleus and cytoplasm of all eukaryotic cells. Apoptosis activation induced by ubiquitin-proteasome pathway inhibition makes the proteasome a new target of anticancer therapy. Bortezomib is the first proteasome inhibitor to be approved by the US FDA; in 2003 as a third line and in 2005 as a second line therapy for the treatment of multiple myeloma only. This review focuses on the use of bortezomib, not only in its therapeutic role but also, more specifically, in its biologic role and discusses the most recent applications of the drug in solid tumors, both at a preclinical and clinical level.

Drugubiquitin-proteasome pathway proteasome inhibitorsSettore MED/06 - Oncologia Medicamedia_common.quotation_subjectClinical BiochemistryDrug Evaluation PreclinicalAntineoplastic AgentsApoptosisPharmacologyBortezomibNeoplasmsDrug DiscoverymedicineAnimalsHumansMultiple myelomamedia_commonPharmacologyClinical Trials as Topicbusiness.industryBortezomibmedicine.diseaseBoronic AcidsProteasomeClinical evidenceCytoplasmApoptosisPyrazinesProteasome inhibitorMolecular Medicinebusinessmedicine.drug
researchProduct

Dryofragin, a phloroglucinol derivative, induces apoptosis in human breast cancer MCF-7 cells through ROS-mediated mitochondrial pathway

2012

Dryofragin is a phloroglucinol derivative extracted from Dryopteris fragrans (L.) Schott. In this study, the anticancer activity of dryofragin on human breast cancer MCF-7 cells was investigated. Dryofragin inhibited the growth of MCF-7 cells in a time and concentration-dependent manner. The cell viability was measured using MTT assay. After treatment with dryofragin for 72, 48 and 24 h, the IC₅₀ values were 27.26, 37.51 and 76.10 μM, respectively. Further analyses of DNA fragmentation and Annexin V-PI double-labeling indicated an induction of apoptosis. Dryofragin-treatment MCF-7 cells had a significantly accumulation of reactive oxygen species (ROS), as well as an increased percentage of …

DryopterisApoptosisBreast NeoplasmsPhloroglucinolBiologyToxicologyAnnexinCell Line TumorHumansMTT assayBreastViability assayMembrane Potential Mitochondrialchemistry.chemical_classificationReactive oxygen speciesGeneral MedicineAntineoplastic Agents PhytogenicMolecular biologyMitochondriaCell biologychemistryMCF-7Cell cultureApoptosisDNA fragmentationFemaleReactive Oxygen SpeciesSignal TransductionChemico-Biological Interactions
researchProduct

Furostanol saponins and ecdysones with cytotoxic activity from Helleborus bocconei ssp. intermedius

2009

Two furostanol saponins helleboroside A (1) and helleboroside B (2) were isolated from the methanol extract of Helleborus bocconei Ten. subsp. intermedius (Guss.) Greuter and Burdet, along with the furospirostanol saponin 4 and two ecdysones: ecdysterone (5) and polypodyne B (6). Compound 2 was enzymatically hydrolysed to give product 3. The biological activity of all compounds was tested against rat C6 glioma cells showing a significant cytotoxicity for compounds 3, 4 and 6. Copyright © 2009 John Wiley & Sons, Ltd.

EcdysoneStereochemistryHelleborusSaponinRanunculaceaePharmacognosyCell Linefurostanol saponinC6 glioma cellAnimalsSettore BIO/15 - Biologia FarmaceuticaMedicinal plantsCytotoxicitycytotoxic activityPharmacologychemistry.chemical_classificationMolecular StructureTraditional medicinebiologyPlant ExtractsGlycosideBiological activitySettore CHIM/06 - Chimica OrganicaSaponinsbiology.organism_classificationAntineoplastic Agents PhytogenicRatsHelleborusSterolschemistryH. bocconei subsp. intermediuRanunculaceae
researchProduct

Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.

2007

Cytotoxic chemotherapies are standard of care for patients suffering from advanced non-small cell lung cancer (NSCLC). However, objective responses are only achieved in 20% of cases and long-term survival is rarely observed. Clinically applied anticancer drugs exert at least some of their activities by inducing apoptosis. A critical step in apoptotic signal transduction is the permeabilization of the mitochondrial outer membrane (MOM), which is regulated by the BCL-2 family of proteins. Hence, therapeutic targeting of BCL-2 proteins is a promising approach to increase the drug-sensitivity of cancers. To this end we have assessed the impact of conditional expression of the proapoptotic multi…

ElectrophoresisCancer ResearchProgrammed cell deathLung NeoplasmsPaclitaxelmedicine.medical_treatmentImmunoblottingAntineoplastic AgentsApoptosisDrug resistanceBiologyPermeabilityPiperazinesTargeted therapyNitrophenolsCarcinoma Non-Small-Cell LungCell Line TumormedicineCytotoxic T cellHumansLung cancerEtoposideSulfonamidesBcl-2 familyBiphenyl CompoundsButylated Hydroxytoluenemedicine.diseaseFlow CytometryImmunohistochemistryMitochondriaNeoplasm ProteinsGene Expression Regulation Neoplasticbcl-2 Homologous Antagonist-Killer ProteinOncologyProto-Oncogene Proteins c-bcl-2ApoptosisDoxorubicinDrug Resistance NeoplasmImmunologyCancer researchMyeloid Cell Leukemia Sequence 1 ProteinSignal transductionSignal TransductionInternational journal of cancer
researchProduct

A novel approach for analysis of oligonucleotide-cisplatin interactions by continuous elution gel electrophoresis coupled to isotope dilution inducti…

2008

In this work we present a novel approach for in vitro studies of cisplatin interactions with 8-mer oligonucleotides. The approach is based on the recently developed coupling of continuous elution gel electrophoresis (GE) to an inductively coupled plasma-sector field mass spectrometer (ICP-SFMS) with the aim of monitoring the interaction process between this cytostatic drug and the nucleotides. In contrast to existing methods, the electrophoretic separation conditions used here allow both the determination of the reaction kinetics in more detail as well as the observation of dominant intermediates. Two different nucleotides sequences have been investigated for comparison purposes, one contai…

ElectrophoresisChromatographyProtein mass spectrometryElutionChemistryClinical BiochemistryAnalytical chemistryOligonucleotidesAntineoplastic AgentsMass spectrometryBiochemistryCapillary electrophoresis–mass spectrometrySample preparation in mass spectrometryAnalytical ChemistrySurface-enhanced laser desorption/ionizationMatrix-assisted laser desorption/ionizationKineticsSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationCisplatinInductively coupled plasma mass spectrometryElectrophoresis
researchProduct

IL-6 stimulates annexin 1 expression and translocation and suggests a new biological role as class II acute phase protein.

1998

Annexin 1 (Ax 1), a protein whose synthesis and secretion are induced during the inflammatory response, has been proposed as a mediator of the anti-inflammatory action of glucocorticoids. To gain insight into a broader role of Ax 1 during the inflammatory response, the authors have investigated how pro-inflammatory cytokines [interleukin 1 (IL-1), IL-6 and tumour necrosis factor alpha (TNF-alpha)] affect Ax 1 expression and regulation at transcriptional and translational levels. The authors show that induction of the Ax 1 protein and its translocation to the cell membrane are stimulated by interleukin 6. However neither IL-1 nor TNF-alpha display these effects. Analysis of 5'-deletion mutan…

ElectrophoresisImmunologyAdenocarcinomaBiochemistryDexamethasoneMediatorAnnexinTumor Cells CulturedImmunology and AllergyHumansSecretionRNA MessengerCloning MolecularInterleukin 6Promoter Regions GeneticMolecular BiologyAnnexin A1Reporter genebiologyInterleukin-6Acute-phase proteinInterleukinNuclear ProteinsHematologyMolecular biologyRecombinant ProteinsDNA-Binding ProteinsGene Expression Regulation NeoplasticMifepristonebiology.proteinCCAAT-Enhancer-Binding ProteinsMutagenesis Site-DirectedTumor necrosis factor alphaAcute-Phase ProteinsTranscription FactorsCytokine
researchProduct